| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/00004714-199812000-00003 |
| P698 | PubMed publication ID | 9864074 |
| P50 | author | Charles M. Beasley | Q44812337 |
| Frederic M. Quitkin | Q109460058 | ||
| P2093 | author name string | E Schweizer | |
| J F Rosenbaum | |||
| J Fawcett | |||
| F W Reimherr | |||
| J D Amsterdam | |||
| F Garcia-España | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | fluoxetine | Q422244 |
| P304 | page(s) | 435-440 | |
| P577 | publication date | 1998-12-01 | |
| P1433 | published in | Journal of Clinical Psychopharmacology | Q6294969 |
| P1476 | title | Efficacy and safety of fluoxetine in treating bipolar II major depressive episode | |
| P478 | volume | 18 |
| Q34121398 | "Cade's disease" and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder |
| Q36074720 | 'Bipolar missed states': the diagnosis and clinical salience of bipolar mixed states |
| Q37574210 | A case-control study of bipolar depression, compared with unipolar depression, in a regional hospital in Hong Kong |
| Q35680384 | A review of antidepressant-induced hypomania in major depression: suggestions for DSM-V. |
| Q35111584 | Acceleration and augmentation strategies for treating bipolar depression |
| Q51945834 | Advances in the Pharmacological Treatment of Bipolar Affective Disorders |
| Q36248038 | Antidepressant-induced manic conversion: a developmentally informed synthesis of the literature |
| Q73887624 | Atypical depression with hypomanic symptoms |
| Q35089923 | Avoiding drug-induced switching in patients with bipolar depression |
| Q34497641 | Bipolar II and the bipolar spectrum. |
| Q34662637 | Bipolar II disorder : epidemiology, diagnosis and management |
| Q36011833 | Bipolar II disorder: a review |
| Q36023392 | Bipolar II disorder: an overview of recent developments |
| Q35017636 | Bipolar depression: management options |
| Q34052825 | Bipolar depression: pharmacotherapy and related therapeutic strategies |
| Q34108306 | Bipolar disorder in youth |
| Q34675235 | Bipolar spectrum disorders. New perspectives |
| Q73605608 | Borderline personality disorder and bipolar II disorder in private practice depressed outpatients |
| Q52656684 | Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. |
| Q34809427 | Class effect of pharmacotherapy in bipolar disorder: fact or misbelief? |
| Q38584955 | Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. |
| Q37171940 | Effect of Fluoxetine Consumption on Orthodontic Tooth Movement in Rats |
| Q33950999 | Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode |
| Q38092894 | Efficacy and safety of fluoxetine monotherapy in bipolar depression: a systematic review |
| Q33959019 | Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study |
| Q38012647 | Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry |
| Q38176400 | Emerging drugs for bipolar depression: an update |
| Q48685213 | Factor analysis of the Montgomery Asberg Depression Rating Scale in 251 bipolar II and 306 unipolar depressed outpatients |
| Q43728696 | Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression |
| Q35561522 | Gender differences in bipolar disorder |
| Q51509688 | General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. |
| Q33920209 | Historical perspectives and natural history of bipolar disorder |
| Q46252301 | Major Depressive Disorder with Anger: A Bipolar Spectrum Disorder? |
| Q35365581 | Management of Bipolar II Disorder |
| Q27012673 | Management of bipolar I depression: clinical utility of lurasidone |
| Q41808917 | Pharmaceutical treatment of acute bipolar depression |
| Q34349641 | Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis |
| Q35954969 | Pharmacotherapy for the treatment of acute bipolar II depression: current evidence |
| Q35680377 | Pharmacotherapy of bipolar II disorder: a critical review of current evidence |
| Q34106689 | Pharmacotherapy of depression and mixed states in bipolar disorder. |
| Q73466905 | Psychotic versus nonpsychotic bipolar outpatient depression |
| Q43931805 | Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers |
| Q35967580 | Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse-prevention of bipolar II depression: A randomized, double-blind, parallel-group, prospective study |
| Q42558462 | Serotonin transporter gene polymorphism and treatment response to serotonin reuptake inhibitor (escitalopram) in depression: An open pilot study |
| Q44783521 | Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression - low manic switch rate |
| Q36754503 | Short-term venlafaxine v. lithium monotherapy for bipolar type II major depressive episodes: effectiveness and mood conversion rate. |
| Q37794043 | Switching to Hypomania and Mania: Differential Neurochemical, Neuropsychological, and Pharmacologic Triggers and Their Mechanisms |
| Q28066714 | The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm |
| Q30583384 | The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders |
| Q34616633 | The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression |
| Q34649187 | The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder |
| Q38040453 | The argument of antidepressant drugs in the treatment of bipolar depression: mixed evidence or mixed states? |
| Q37292350 | The contemporary face of bipolar illness: complex diagnostic and therapeutic challenges. |
| Q36162402 | Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder |
| Q82351280 | Treatment-resistant bipolar disorder |
| Q35845683 | Unmet needs in bipolar depression |
| Q73897688 | Venlafaxine monotherapy in women with bipolar II and unipolar major depression |
| Q89665761 | Working With a Patient With Bipolar I Disorder Who Is Experiencing Depression |
| Q35024109 | World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression |
| Q53855360 | [Manic episodes during antidepressant treatment in bipolar disorder]. |
Search more.